Gilead Sciences Inc (GILD) Valuation
Historical valuation analysis based on 500 data points (2024-08-30 to 2026-08-28)
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition o...
Gilead Sciences Inc (GILD) currently trades at a P/E ratio of 20.14 (historical range: 16.53–1169.44, median: 22.40), placing it at the 36th percentile — below its historical average, P/S ratio of 6.24 (range: 3.53–6.72, 94th percentile — expensive relative to its history), EV/EBITDA of 80.34 (range: 17.30–104.73, 85th percentile).
Over the historical period (2024-08-30 to 2026-08-28), Gilead Sciences Inc's P/E ratio has contracted by 96% over the observed period (from an average of 491.0 to 19.5).
Gilead Sciences Inc appears slightly overvalued relative to its historical range, with most valuation metrics above their median levels.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/E Ratio | 20.14 | 16.53 | 22.40 | 1169.44 | 36th | below its historical average |
| P/S Ratio | 6.24 | 3.53 | 5.02 | 6.72 | 94th | expensive relative to its history |
| EV/EBITDA | 80.34 | 17.30 | 66.64 | 104.73 | 85th | expensive relative to its history |
| FCF Yield | 0.01 | 0.01 | 0.03 | 0.09 | 11th | expensive relative to its history |